Pfizer Shares Data for First-of-its-Kind NSCLC Drug Targeting EML4-ALK Mutations in Cancer Cells

The drug "is the first agent in clinical development that selectively targets a unique genetic feature of cancer cells," Pfizer said in a statement released at ASCO's annual meeting here this week.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.